Section 1

Preview this deck

Children- Poison Prevention Packaging Act

Front

Star 0%
Star 0%
Star 0%
Star 0%
Star 0%

0.0

0 reviews

5
0
4
0
3
0
2
0
1
0

Active users

2

All-time users

3

Favorites

0

Last updated

1 year ago

Date created

Mar 1, 2020

Cards (123)

Section 1

(50 cards)

Children- Poison Prevention Packaging Act

Front

80 % can't open the cap

Back

Adults- Poison Prevention Packaging Act

Front

90 % can open the cap

Back

Conjugated estrogen in mnemomiuc dispenser

Front

NMT 32 mg of the drug

Back

Bioequivalence

Front

Extent and Rate of the drug absorbed the same except if it 1. makes no medical difference 2. documented 3. not essential to effect

Back

Poison Prevention Packaging Act of 1970

Front

Requires use of child-resistant containers

Back

Potassium supplements

Front

NMT 50 meQ/dose

Back

Components of REMS

Front

1. Medication guides 2. Communication plans 3. Elements to assure safe use

Back

Right to Try

Front

1. Terminally ILL 2. Phase I trial 3. No FDA oversight 4.Manufacturer approval

Back

Betamethasone

Front

NMT 12.6 mg drug/pkg

Back

Investigation New Drug used when

Front

1. There is not comparable drug 2. There is no alternative drug 3. There is no controlled trials, or all trials completed

Back

Waxman-Hatch Act

Front

+Clinical studies are not needed for generics

Back

Can physicians make blanket prescriptions?

Front

No they can not

Back

Prednisone

Front

NMT 105 mg/pkg

Back

Prescription refills in PA

Front

1.Medication can not be substituted for another medication unless 1. Call pt and get approval 2. Call prescriber and get approval

Back

Drugs products that have a _____ therapeutic window will not be considered therapeutically equivalent

Front

narrow

Back

Nitroglycerin

Front

not required to be in CRC packaging

Back

Methylprednisone Tablets

Front

NMT 84 mg of drug/pkg

Back

Hospitals

Front

sometimes do not meet therapeutically equivalent products

Back

Aerosol prepaations intenteded for inhalation

Front

N/A

Back

REMS

Front

Risk Evaluation and Mitigation Strategy- the benefits of using it must outweigh risks

Back

B in the Orange book

Front

B means a documented or potential bioequivalence problem (does not mean it is worse than reference)

Back

STEPS

Front

Thialodmide

Back

What does a generic drug need to prove for generic equivalence?

Front

1. Bioequivalence 2. Bio availability 3. GMP

Back

Anhydrous chloestyramine

Front

N/A

Back

Mebendazole

Front

NMT 600 mg drug/pkg

Back

can you reuse child-resistant packaging?

Front

Only glass vials as long as new CRC cap is used

Back

Erythromycin granules tablets

Front

NMT 8 gm of erythromycin NMT 16 grams

Back

What if I can't reach the doctor but can reach the patient?

Front

Notify the doctor as soon as possible that you filled prescription from different manufacturer in emergency situation- legal

Back

Can manufacturers produce one package that is not child resistant?

Front

Yes, manufacturers can if they state on package is for households without young children or package not child resistant

Back

Oral contracpetives

Front

N/A

Back

A in the Orange book

Front

A means that a drug is therapeutically equivalent

Back

General rule: CRC

Front

all drugs must be in CRC

Back

Sodium Flouride

Front

NMT 110 mg of Sodium Flouridw per package ( 50 mg per package)- CRC

Back

Therepeutic equivalents have the same

Front

Active Ingredient Strength Dosage Form

Back

isosorbide dinitrate SL or chewable

Front

NMT 10 mg or less-CRC

Back

Orange book is not federal law

Front

drugs are substituted that sometimes that are not therapeutically equivalent; however, most states do this.

Back

Medroxyprogestrone

Front

N/A

Back

Patent term extensions

Front

2-5 years New indication can be marketed for three years no generic drug for five years

Back

Pharmaceutical equivalents that are bio equivalent

Front

assumed to be therapeutically equivalent

Back

Pancrealipase preparations

Front

N/A

Back

REMS safe use

Front

1. Special training or certification 2. Restricting distribution 3. Dispensing based on evidence safe conditions 4. Pt monitoring One or more

Back

Waxman- Hatch Amendments

Front

how generic drugs get approved

Back

OTC

Front

Are mostly approved through monograph

Back

Colespitol

Front

up to 5 gm

Back

FTC comission monitors

Front

marketing of OTC drugs

Back

Therepeutic equivalents are Pharmceutical equivalents but with

Front

same ClinicaL EFFECT and efficacy

Back

Poison Prevention Packaging Act of 1970- enforced by

Front

Consumer Product Safety

Back

Unit dose- Under Poison Prevention Packaging Act

Front

can't open more than eight doses or toxic amount, whichever is less

Back

How to define a narrow therapeutic window drug?

Front

1. Less than a two fold difference between toxic dose and effective dose 2. Less than a two fold difference between lethal dose and effective dose 3. Carbamezepine, Phenyotin, warfarin, lithium, clonidine, levothyroxine

Back

FDA monitors

Front

marketing of prescription drugs

Back

Section 2

(50 cards)

Injunctive

Front

bring manufacturer to court

Back

In case of antibiotic drugs being provided for the manufacturer in granular form to be reconstituted by pharmacist, whose responsibility is it to provide child-resistant packaging?

Front

the pharmacist and manufacturer

Back

Whose responsibility maintains PPA?

Front

it is the dispensing pharmacist

Back

Good Manufacturing Practices

Front

Federal guidelines that must be followed by all entities that prepare and package medication or medical devices ( manufacturing, processing, packaging holding)

Back

If you think you have package site ,that is not susceptible to wear?

Front

Get information from manufacturer it is not susceptible to wear

Back

Sacrosidise in glycerol and water

Front

N/A

Back

Class I Recall

Front

Recall class where there is a reasonable possibility that the use/exposure to a violative product will cause serous adverse effects on health or death

Back

Dotterwich Case

Front

mislabeled information by accident

Back

Adulteration and Misbranding

Front

Most all violations of the FDCA are either ____ or ____, or both.

Back

Can I dispense easy open to nursing home?

Front

Yes, traditional nursing home where nurse can give med= institutions not needed.

Back

Adulteration

Front

making unpure poorer in quality

Back

Child resistant

Front

80 percent can't get acess to meds children less than 5 90 percent of adults can open it

Back

Who is ultimately responsible something complies with the PPPA of 1970?

Front

the pharmacist

Back

Class III recall definition

Front

Unlikely to cause adverse health consequences * typo)

Back

Poison Prevention Packaging Act of 1970- dosage form

Front

This is only for oral medications

Back

Park Case

Front

Acme put food in bad places and unsanitary places

Back

Can a physcian make a blanket waiver?

Front

No physician can not- only prescription can be filled this way

Back

drug recall: good faith defense?

Front

No, you did not check mail

Back

Seizure

Front

seize drugs off the shelf

Back

Items that don't need to be in tamper evidence packaging

Front

Dermatological Dentrifice Insulin Lozenge

Back

Park Doctrine

Front

Park Case and Dottewich Case

Back

May the individual request that all of his/ her prescriptions be filled in conventional ( non-special packaging)?

Front

Yes; however one request is not a blanket waiver

Back

If a pt calls for information for poisoning?

Front

If you do not have emergency info needed, then call poison control center 1-800-222-1222

Back

F & D C 301 Prohibitions

Front

Adulteration and Misbranding

Back

Pudue Pharma

Front

downplayed oxycontin marketed as misbranding

Back

FDA: can it order removal of device off market

Front

YES it can

Back

FDA: can it order a drug off market

Front

No it can't

Back

Class II Recall

Front

The probability of serious harm is not likely and the effects may be temporary or reversable. This recall does not go to the customer level and is usually due to problems with consistency of potency ( remote probability of serious adverse effect)

Back

FDA can't directly order

Front

a drug to be removed from market

Back

Non-prescription packaging one size that does not comply

Front

is applicable

Back

Norethindrone

Front

50 mg of drug

Back

prescription vial failure

Front

if child gains acess to mes

Back

Where all the expemptions listed for the PPPA?

Front

PPPA regulations 16 CFR 1700 .14

Back

Unit dose packaging failure

Front

child gains access to those that have 8 or more pills or toxic dose

Back

PACKAGING PPPA VIOLATION

Front

CIVIL CRIMINAL ADMINISTRATIVE PENALTIES

Back

Mislabeling: good faith defense?

Front

Yes

Back

FDA enforcement act

Front

Injuctive relief ( seek court action) Seizure ( libel action)- take drugs off shelf Criminal proceedings- (fines and imprisonments) Warning letter

Back

What is the responsbility of the pharmacist under PPPA?

Front

Poison Prevention packaging ACT- To dispense medication in poison control container unless patient, prescriber, or exceptions

Back

Must the customer make the choice for the conventional packaging in writing?

Front

No; however to protect yourself you might want to

Back

Did not catch recall?

Front

Civil liability

Back

Are IND susceptible to PPPAs standard?

Front

Yes

Back

FDA will inspect blank to determine_______ Adulteration

Front

1. The plant not every product 2. Health and safety better for community if FDA can monitor

Back

HRT that relies on progesterone and estrogen

Front

N/A

Back

What if you violate the PPPA?

Front

YOU CAN GO TO JAIL FOR A YEAR AND FINED UP TO 250,000 500,000 FINED ORGANIZATION AND CIVILLY PROSECUTED IF HURT SOMEONE

Back

Prescription packaging one size that does not comply

Front

is not applicable

Back

Can a physician check a box to do this easy open waiver?

Front

Yes, prescribe can do this however not encouraged due to over non-child resistant caps

Back

Criminal proceedings

Front

against manufacturer

Back

Can I dispense easy open containers in hopsital?

Front

Yes, as long as patient is confined to hospital; however not in patient going out of hospital.

Back

Misbranding/ Adulteration- Ask youself?

Front

Strength, Quality, Purity

Back

warning letter

Front

to manufacturer

Back

Section 3

(23 cards)

Prescription Refill Authority

Front

1. Secretary- can authorize refill 2. Doctor can tell secretary to authorize refill ( Doctor must authorize- nurse or secretary can't) 3. Secretary- can relay info to Pharmacist

Back

IRB

Front

protects the health and welfare for pts.

Back

Tampered or not?

Front

1. Stopped by distinctive with design 2. Mess up logo could be tampered

Back

25 percent

Front

less than 2 years repack then need to take 25 percent of time

Back

Number ( for new drug)

Front

chemical type

Back

Misbranding

Front

the label is false or misleading packaged or labeled in violation of PPPA Pharmacist sells a drug without prescription or refills prescription without authorization

Back

Some prescriptions can be

Front

otc and rx

Back

if a drug gets a new indication

Front

by FDA approval NDA to get it approved for that use

Back

Supplemental NDA

Front

any minor changes in the Drug

Back

If something is not in tamper evident packaging that should be violation of

Front

adulteration, misbranding, or both

Back

Misbranding and Advertising

Front

Side effects, contraindications, and effectivenss

Back

Beyond use date for prescription vial

Front

1. Beyond use date not later than expiration 2. or one year from dispensing the medication Whichever is sooner

Back

phase IV study

Front

continual evaluation of a drug after it has been released for marketing ( need to let FDA safety and efficacy)

Back

Beyond use date USP guidelines

Front

not adopted

Back

Drug facts panel

Front

- Active ingredients - Purpose -Use - Warnings - Directions - Other info directed as monograph -Inactive Ingredients -Questions

Back

PA requirment beyond use date

Front

If less than a year, Do not use after ______ (date)

Back

S

Front

drug that is already equivalent

Back

P

Front

priority drug - more effective -more effective or safer - greater convenience, less side effects, and improved tolerance or usefulness

Back

Beyond use date of 9/01/18 expiration needs to be

Front

09/01/20

Back

Items that do need to be in tamper evident package

Front

OTX drugs, cosmetics, vaginal products, contact lenses, gelatin capsules

Back

Prescriptive Authority

Front

Each state will have different prescriptive authority for different practiotioners

Back

Letter

Front

therapeutic potential

Back

Switch of Prescription Drugs to OTC

Front

A switch may occur in three ways: 1)The manufacturer may request the switch. Submit a supplemental application to its approved NDA - marketing exclusivity -from different manufacturer drug could be RX 2) Manufacturer can petition FDA FDA- add a monograph or amend an existing monograph

Back